Related Articles
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer
Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR‑T790M mutant lung cancer
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation